Anti Inflammatory News and Research

RSS

UAB's Undiagnosed Diseases Program finds answers for mysterious health issues

Stephanie and Christopher Smith have been on a long, difficult and often frustrating journey to find answers for the mysterious health issues of their children. It started 24 years ago when their third child, Gage, was born. Gage, his younger brother Aiden and then sister Mandalynn, now 13, all developed mysterious symptoms that mystified doctors.

29 Dec 2015

Body can control pathogen-induced inflammatory response, find Georgia State researchers

The body can control inflammatory response triggered by invasions of microbial pathogens, such as bacteria and viruses, a discovery that could lead to the development of new therapeutic agents for uncontrolled inflammation, according to researchers at Georgia State University.

29 Dec 2015

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Diabetes is the leading cause of kidney failure, and scientists have found that infusing just a small dose of a cytokine, thought to help cause that failure, can instead prevent or reverse it.

29 Dec 2015

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

Large doses of vitamin A reduce severity of gastrointestinal disease in mice

After observing that some gastrointestinal disease in premature human and mouse infants progresses only when certain immune system white blood cells go into inflammatory overdrive, Johns Hopkins researchers have found that giving large doses of vitamin A to mice converts those blood cells into inflammation suppressors and reduces the severity of the disease, compared to untreated mice.

22 Dec 2015

New treatment strategy may take pain away

A brain region controlling whether we feel happy or sad, as well as addiction, is remodeled by chronic pain, reports a new Northwestern Medicine study.

22 Dec 2015

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis.

21 Dec 2015

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study.

18 Dec 2015

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

A team of scientists at the University of Nebraska Medical Center (UNMC) and Longevity Biotech, Inc., has demonstrated that neuroprotection could be attained in preclinical models by a novel drug candidate that changes immune responses.

18 Dec 2015

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Cancer drug may protect kidneys from damage caused by chemotherapy agent cisplatin

A class of drugs used increasingly to help fight cancer may have the additional benefit of protecting the kidneys when packaged with the powerful chemotherapy agent cisplatin.

16 Dec 2015

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA).

15 Dec 2015

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

Paying close attention to results of simple blood test can help predict risk of kidney failure, death

Kidney disease in the United States is both common and under-diagnosed, but two new studies led by Johns Hopkins Bloomberg School of Public Health researchers suggest that paying close attention to results of a simple blood test can help predict the likelihood that patients are headed for kidney failure or death.

13 Dec 2015

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS.

11 Dec 2015

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research.

7 Dec 2015

New GASMAS-based technique shows promise for non-invasive sinusitis diagnostics

A team of scientists from the South China Normal University (Guangzhou, China) and the Lund University (Sweden) led by Sune Svanberg now presents a new approach for a non-intrusive optical technique for human sinus realtime diagnostics that could be developed into a cost-effective, easy-to-use hand-held instrument.

7 Dec 2015

Could statins treat muscular dystrophy? An interview with Dr. Nick Whitehead and Dr Stan Froehner

In addition to their well established cholesterol lowering benefits, statins also have potent anti-inflammatory, anti-fibrotic and antioxidant effects, which continue to be identified in a wide range of diseases.

30 Nov 2015

Testosterone treatment can benefit men with Type 2 diabetes

Men with Type 2 diabetes who have low testosterone levels can benefit significantly from testosterone treatment.

30 Nov 2015

Anti Inflammatory News and Research

UAB's Undiagnosed Diseases Program finds answers for mysterious health issues

Body can control pathogen-induced inflammatory response, find Georgia State researchers

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Large doses of vitamin A reduce severity of gastrointestinal disease in mice

New treatment strategy may take pain away

SciClone plans to pursue development of SGX942 in the Greater China market

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Cancer drug may protect kidneys from damage caused by chemotherapy agent cisplatin

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Paying close attention to results of simple blood test can help predict risk of kidney failure, death

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

New GASMAS-based technique shows promise for non-invasive sinusitis diagnostics

Could statins treat muscular dystrophy? An interview with Dr. Nick Whitehead and Dr Stan Froehner

Testosterone treatment can benefit men with Type 2 diabetes

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News